Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV

Cancer Microenvironment

Volumn 8, Issue 3, 2015, Pages 201-207

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; HIV 1; Immune Regulation; Immunotherapy; Treg

Indexed keywords

5' NUCLEOTIDASE; CD3 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENILEUKIN DIFTITOX; GAMMA INTERFERON; GLYCOPROTEIN A REPETITION PREDOMINANT; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; LATENCY ASSOCIATED PEPTIDE; NEUROPILIN 1; PEPTIDES AND PROTEINS; PERFORIN; SEMAPHORIN; SEMAPHORIN 4A; SUNITINIB; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; NEOPLASM; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84955203406     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-014-0159-1     Document Type: Article

References (59)

1. Duhen T, Duhen R, Lanzavecchia A et al (2012) Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119:4430–4440. doi:10.1182/blood-2011-11-39324
2. Burocchi A, Colombo MP, Piconese S (2013) Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol 4:247. doi:10.3389/fimmu.2013.00247
3. Mougiakakos D, Choudhury A, Lladser A et al (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57–117. doi:10.1016/S0065-230X(10)07003-X
4. Long SA, Buckner JH (2011) CD4 + FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 187:2061–2066. doi:10.4049/jimmunol.1003224
5. Addey C, White M, Dou L et al (2011) Functional plasticity of antigen-specific regulatory T cells in context of tumor. J Immunol 186:4557–4564. doi:10.4049/jimmunol.1003797
6. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 9:942–949
7. Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60(7):909–918. doi:10.1007/s00262-011-1046-y
8. Rech AJ, Mick R, Kaplan DE et al (2010) Homeostasis of peripheral FoxP3(+) CD4(+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 9:599–607. doi:10.1007/s00262-009-0780-x
9. Fridman WH, Galon J, Pagès F et al (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71(17):5601–5605. doi:10.1158/0008-5472.CAN-11-1316
10. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of FOXP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18:3022–3029. doi:10.1158/1078-0432.CCR-11-3216
11. Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63:67–72. doi:10.1007/s00262-013-1490-y
12. Angin M, Sharma S, King M, Murooka TT, et al. (2014) HIV-1 infection impairs regulatory T cell suppressive capacity on a per-cell basis. J Infect. Dis. (Epub ahead of print)
13. Whiteside TL, Schuler P, Schilling B (2012) Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12:1383–1397. doi:10.1517/14712598.2012.707184
14. Borsellino G, Kleinewietfeld M, Di Mitri D et al (2007) Expression of ectonucleotidase CD39 by FoxP3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:1225–1232
15. Deaglio S, Dwyer KM, Gao W et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–1265
16. Schuler PJ, Macatangay BJ, Saze Z et al (2013) CD4 + CD73+ T cells are associated with lower T cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 27:1545–1555. doi:10.1097/QAD.0b013e328360c7f3
17. Abbas AK, Benoist C, Bluestone JA et al (2013) Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 14:307–308. doi:10.1038/ni.2554
18. Bergmann C, Strauss L, Zeidler R et al (2007) Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67:8865–8873
19. Canavan JB, Afzali B, Scotta C et al (2012) A rapid diagnostic test for human regulatory T cell function to enable regulatory T cell therapy. Blood 119:e57–e66. doi:10.1182/blood-2011-09-380048
20. Ruitenberg JJ, Boyce C, Hingorani R, et al. (2011) Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Methods 372:95–106. doi: 10.106/j.jim.2011.07.001
21. Vukmanovic-Stejic M, Zhang Y, Cook JE et al (2006) Human CD4+ CD25hi FOXP3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116:2423–2433
22. Mandapathil M, Hilldorfer B, Szczepanski MJ et al (2010) Generation and accumulation of immunosuppressive adenosine by human CD4 + CD25highFOXP3+ regulatory T cells. J Biol Chem 285:7176–7186. doi:10.1074/jbc.M109.047423
23. Schuler PJ, Saze Z, Hong CS et al (2014) Human CD4(+) CD39(+) regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73(+) exosomes or CD73(+) cells. Clin Exp Immunol. doi:10.1111/cei.12354
24. Stockis J, Colau D, Coulie PG, Lucas S (2009) Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 39:3315–3322. doi:10.1002/eji.200939684
25. Tran DQ, Andersson J, Wang R et al (2009) GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 106:13445–13450. doi:10.1073/pnas.0901944106
26. Sun J, Tang DN, Fu T, Sharma P (2012) Identification of human regulatory T cells in the setting of T cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov 2:122–130. doi:10.1158/2159-8290.CD-11-0236
27. Strauss L, Bergmann C, Whiteside TL (2009) Human circulating CD4 + CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 182:1469–1480
28. Czystowska M, Strauss L, Bergmann C et al (2010) Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 88:577–588. doi:10.1007/s00109-010-0602-9
29. Schuler PJ, Harasymczuk M, Schilling B et al (2013) Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 19:6585–6596. doi:10.1158/1078-0432.CCR-13.0900
30. Jie HB, Gildener-Leapman N, Li J et al (2013) Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109(10):2629–2635. doi:10.1038/bjc.2013.645
31. Whiteside TL. (2014) Induced regulatory T cells (iTreg) in inhibitory microenvironments created by cancer. Expert Opin. Biol. Ther. In press.
32. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523–532. doi:10.1038/nri2343
33. Catalfamo M, Wilhelm C, Tcheung L et al (2008) CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 186(4):2106–2116. doi:10.4049/jimmunol.1002000
34. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM (2002) CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 169(6):3400–3406
35. Antonioli L, Blandizzi C, Pacher P, Hasko G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13:842–857. doi:10.1038/nrc3613
36. Muller-Haegelc S, Muller L, Whiteside TL. (2014) Immuno-regulatory activity of adenosine and its role in human cancer progression. Exp. Rev. Clin. Immunol. In Press
37. Mandapathil M, Szczepanski MJ, Szajnik M et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285:27571–27580. doi:10.1074/jbc.M110.127100
38. Mandapathil M, Szczepanski M, Harasymczuk M et al (2012) CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 1(5):659–669
39. Ryzhov S, Novitskiy SV, Goldstein AE et al (2011) Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b + Gr1+ cells. J Immunol 187(11):6120–6129. doi:10.4049/jimmunol.1101225
40. Ohta A, Kini R, Ohta A et al (2012) The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 3:190. doi:10.3389/fimmu.2012.00190
41. Bergmann C, Strauss L, Wang Y et al (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706–3715. doi:10.1158/1078-0432.CCR-07-5126
42. Mandapathil M, Whiteside TL (2011) Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E2 cooperation. Expert Opin Biol Ther 11:1203–1214. doi:10.1517/14712598.2011.581225
43. Whiteside TL, Jackson EK (2013) Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol 4:212. doi:10.3389/fimmu.2013.00212
44. Schulze Zur Wiesch J, Thomssen A, Hartjen P et al (2011) Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 85(3):1287–1297. doi:10.1128/JVI.01758-10
45. Macatangay BJ, Szajnik ME, Whiteside TL et al (2010) Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 5(3):e9852. doi:10.1371/journal.pone.0009852
46. Ndhlovu LC, Loo CP, Spotts G et al (2008) FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol 83(2):254–262
47. Freguja R, Gianesin K, Mosconi I et al (2011) Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children. Clin Exp Immunol 164(3):373–380. doi:10.1111/j.1365-2249.2011.04383.x
48. Nikolova M, Carriere M, Jenabian MA et al (2011) CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 7(7):e1002110. doi:10.1371/journal.ppat.1002110
49. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72:3439–3444. doi:10.1158/0008-5472.CAN-11-3912
50. Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106. doi:10.1111/j.1749-6632.2009.04939.x
51. Baur AS, Lutz MB, Schierer S et al (2013) Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Blood 122:2185–2194. doi:10.1182/blood-2012-09-456988
52. Finke JH, Rini B, Ireland J et al (2008) Sunitinib reverses type-1immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674–6682. doi:10.1158/1078-0432.CCR-07-5212
53. Elkord E, Alcantar-Orozco EM, Dovedi SJ (2010) T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 10:1573–1586. doi:10.1517/14712598.2010.529126
54. Delgoffe GM, Woo SR, Turnis ME et al (2013) Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501:252–256. doi:10.1038/nature12428
55. Rech AJ, Mick R, Martin S, et al. (2012) CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 4:134ra62. doi: 10.1126/scitranslmed.3003330
56. Schuler PJ, Schilling B, Harasymczuk M et al (2012) Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T cell subsets in cancer patients. Eur J Immunol 42:1876–1885. doi:10.1002/eji.201142347
57. Whiteside TL (2010) Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10:1019–1035. doi:10.1517/14712598.2010.482207
58. Stagg J, Divisekera U, McLaughlin N et al (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 107:1547–1552. doi:10.1073/pnas.0908801107
59. Bastid J, Cottalorda-Regairaz A, Alberici G et al (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32:1743–1751. doi:10.1038/onc.2012.269